Background
Methods
Patients and study design
Variable | n (%) | |
---|---|---|
Age, yr | Median (range) | 53 (28–82) |
Histologic subtype | ||
Ductal, NOS | 181 (92.8) | |
Lobular | 4 (2.1) | |
Micropapillary | 9 (4.6) | |
Solid papillary with invasion | 1 (0.5) | |
Histologic grade | ||
I | 2 (1.0) | |
II | 94 (48.2) | |
III | 99 (50.8) | |
ER status | ||
ER+ | 183 (93.8) | |
ER- | 12 (6.2) | |
PR status | ||
PR+ | 160 (82.1) | |
PR- | 35 (17.9) | |
HER2 status | ||
IHC status | ||
1+ | 10 (5.1) | |
2+ | 185 (94.9) | |
Dual-probe ISH status | ||
± | 195 (100.0) | |
Polysomy 17 | ||
Yes | 137 (70.3) | |
No | 58 (29.7) | |
Ki-67 | ||
<20% | 49 (25.1) | |
≥ 20% | 146 (74.9) | |
TNM stage | ||
T (Primary tumour) | ||
T1 | 93 (47.7) | |
T2 | 98 (50.3) | |
T3 | 1 (0.5) | |
T4 | 3 (1.5) | |
N (Regional lymph nodes) | ||
N0 | 104 (53.3) | |
N1 | 57 (29.2) | |
N2 | 19 (9.8) | |
N3 | 15 (7.7) | |
M (Distant metastasis) | ||
M0 | 192 (98.5) | |
M1 | 3 (1.5) | |
Treatment | ||
Chemotherapy | 159 (81.5) | |
Radiotherapy | 89 (45.6) | |
Hormonal therapy | 123 (63.1) | |
Trastuzumab | 17 (8.7) |
IHC and FISH
Follow-up information
Statistical analysis
Results
Histologic subtype and grade
HER2 status
Molecular subtype
Characteristics | Average HER2 copy number | P value | |||
---|---|---|---|---|---|
4.0–4.4 | 4.5–4.9 | 5.0–5.4 | 5.5–5.9 | ||
Age (year) | 0.15 | ||||
≤ 53 | 32 (50.8) | 41 (61.2) | 20 (40.0) | 5 (33.3) | |
>53 | 31 (49.2) | 26 (38.8) | 30 (60.0) | 10 (66.7) | |
Histopathology | 0.969 | ||||
IDCa | 58 (92.1) | 62 (92.5) | 49 (98.0) | 12 (80.0) | |
Other IBCb | 5 (7.9) | 5 (7.5) | 1 (2.0) | 3 (20.0) | |
Histologic grade | 0.129 | ||||
I | 0 (0.0) | 0 (0.0) | 2 (4.0) | 0 (0.0) | |
II | 27 (42.9) | 34 (50.7) | 23 (46.0) | 10 (66.7) | |
III | 36 (57.1) | 33 (49.3) | 25 (50.0) | 5 (33.3) | |
ER | 0.538 | ||||
Positive | 59 (93.7) | 65 (97.0) | 45 (90.0) | 14 (93.3) | |
Negative | 4 (6.3) | 2 (3.0) | 5 (10.0) | 1 (6.7) | |
PR | 0.257 | ||||
Positive | 48 (76.2) | 57 (85.1) | 43 (86.0) | 12 (80.0) | |
Negative | 15 (23.8) | 10 (14.9) | 7 (14.0) | 3 (20.0) | |
Ki-67 | 0.065 | ||||
< 20% | 19 (30.2) | 20 (29.9) | 7 (14.0) | 3 (20.0) | |
≥ 20% | 44 (69.8) | 47 (70.1) | 43 (86.0) | 12 (80.0) | |
Polysomy 17 | <0.001** | ||||
Yes | 30 (47.6) | 48 (71.6) | 46 (92.0) | 13 (86.7) | |
No | 33 (52.4) | 19 (28.4) | 4 (8.0) | 2 (13.3) | |
Primary Tumor (T) | 0.776 | ||||
T1 | 31 (49.2) | 33 (49.3) | 21 (42.0) | 8 (53.3) | |
T2 | 30 (47.6) | 33 (49.3) | 28 (56.0) | 7 (46.7) | |
T3 | 0 (0.0) | 1 (1.5) | 0 (0.0) | 0 (0.0) | |
T4 | 2 (3.2) | 0 (0.0) | 1 (2.0) | 0 (0.0) | |
Regional Lymph Nodes (N) | 0.806 | ||||
N0 | 32 (50.8) | 40 (59.7) | 25 (50.0) | 7 (46.7) | |
N1 | 20 (31.7) | 15 (22.4) | 17 (34.0) | 5 (33.3) | |
N2 | 8 (12.7) | 6 (9.0) | 3 (6.0) | 2 (13.3) | |
N3 | 3 (4.8) | 6 (9.0) | 5 (10.0) | 1 (6.7) | |
Distant Metastasis (M) | 0.804 | ||||
M0 | 62 (98.4) | 66 (98.5) | 50 (100.0) | 14 (93.3) | |
M1 | 1 (1.6) | 1 (1.5) | 0 (0.0) | 1 (6.7) |
Correlation with Clinicopathological parameters
Prognosis
Factors | Subset | DFS | OS |
---|---|---|---|
P value | P value | ||
Age (year) | ≤ 53 />53 | 0.299 | 0.059 |
Histologic subtype | IDC / Other IBC | 0.917 | 0.978 |
Histologic grade | I / II / III | 0.888 | 0.967 |
ER | Positive / Negative | 0.425 | 0.531 |
PR | Positive / Negative | 0.539 | 0.146 |
HER2 IHC score | 1+ / 2+ | 0.518 | 0.643 |
Average HER2 copy number | 1 / 2 / 3 / 4a | 0.897 | 0.887 |
Ki-67 | < 20% / ≥ 20% | 0.674 | 0.167 |
Target therapy | Yes / No | 0.439 | 0.582 |
T stage | T1 / T2 / T3 / T4 | 0.965 | NA |
N stage | N0 / N1 / N2 / T3 | 0.146 | 0.009* |
M stage | M0 / M1 | 0.003* | 0.000* |